CTMX
CytomX Therapeutics, Inc.
+0.04 (+1.63%)2.81USD1.5M成交股數612M市值–本益比(近四季)33.5股價營收比-92.4%營收年增(近四季)2026-11-05下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 5K |
| 近 180 天 淨額 | −5K |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | 08-05 | Carvajal Alejandra | Chief Legal Officer | A 獲配股票 | 100K | – | – | 100K | SEC |
| 2026-06-15 | 06-17 | Ogden Christopher | Chief Financial Officer | S 公開市場賣出 | 1.6K | 3.05 | 5K | 295K | SEC |
| 2026-03-17 | 03-19 | BELVIN MARCIA | SVP, Chief Scientific Officer | S 公開市場賣出 | 31.5K | 6.42 | 202K | 301K | SEC |
| 2026-03-17 | 03-19 | Chu Yu-Waye | Chief Medical Officer | S 公開市場賣出 | 21.3K | 6.42 | 137K | 189K | SEC |
| 2026-03-17 | 03-19 | McCarthy Sean A. | CEO | S 公開市場賣出(10b5-1) | 119K | 6.42 | 764K | 1.1M | SEC |
| 2026-03-17 | 03-19 | Ogden Christopher | Chief Financial Officer | S 公開市場賣出 | 19.3K | 6.42 | 124K | 297K | SEC |
| 2026-02-02 | 02-04 | McCarthy Sean A. | CEO | A 獲配股票 | 210K | – | – | 1.2M | SEC |
| 2026-02-02 | 02-04 | Chu Yu-Waye | Chief Medical Officer | A 獲配股票 | 75.0K | – | – | 211K | SEC |
| 2026-02-02 | 02-04 | Ogden Christopher | Chief Financial Officer | A 獲配股票 | 90.0K | – | – | 316K | SEC |
| 2026-02-02 | 02-04 | Lester Rachael | Chief Business Officer | A 獲配股票 | 20.0K | – | – | 20.0K | SEC |
| 2026-02-02 | 02-04 | BELVIN MARCIA | SVP, Chief Scientific Officer | A 獲配股票 | 60.0K | – | – | 332K | SEC |
| 2025-11-06 | 11-10 | McCarthy Sean A. | CEO | S 公開市場賣出(10b5-1) | 102K | 4.54 | 462K | 988K | SEC |
| 2025-06-16 | 06-17 | McCarthy Sean A. | CEO | S 公開市場賣出 | 55.5K | 2.69 | 149K | 1.1M | SEC |
| 2025-06-16 | 06-17 | BELVIN MARCIA | SVP, Chief Scientific Officer | S 公開市場賣出 | 13.9K | 2.69 | 37K | 272K | SEC |
| 2025-06-16 | 06-17 | Ogden Christopher | Chief Financial Officer | S 公開市場賣出 | 10.6K | 2.69 | 29K | 226K | SEC |
| 2025-06-13 | 06-17 | BELVIN MARCIA | SVP, Chief Scientific Officer | M 選擇權執行 | 37.5K | – | – | 286K | SEC |
| 2025-06-13 | 06-17 | McCarthy Sean A. | CEO | M 選擇權執行 | 150K | – | – | 1.1M | SEC |
| 2025-06-13 | 06-17 | Ogden Christopher | Chief Financial Officer | S 公開市場賣出 | 1.6K | 2.95 | 5K | 199K | SEC |
| 2025-06-13 | 06-17 | Ogden Christopher | Chief Financial Officer | M 選擇權執行 | 37.5K | – | – | 237K | SEC |
| 2025-03-18 | 03-20 | McCarthy Sean A. | CEO | S 公開市場賣出 | 37.7K | 0.60 | 23K | 995K | SEC |
| 2025-03-18 | 03-20 | BELVIN MARCIA | SVP, Chief Scientific Officer | S 公開市場賣出 | 19.5K | 0.60 | 12K | 249K | SEC |
| 2025-03-18 | 03-20 | Chu Yu-Waye | Chief Medical Officer | S 公開市場賣出 | 4.0K | 0.60 | 2K | 136K | SEC |
| 2025-03-18 | 03-20 | Ogden Christopher | Chief Financial Officer | S 公開市場賣出 | 8.6K | 0.60 | 5K | 201K | SEC |
| 2025-03-18 | 03-20 | ROWLAND LLOYD A | General Counsel | S 公開市場賣出 | 10.2K | 0.60 | 6K | 121K | SEC |
| 2025-02-04 | 02-10 | BELVIN MARCIA | SVP, Chief Scientific Officer | A 獲配股票 | 35.0K | – | – | 211K | SEC |
| 2025-02-04 | 02-10 | BELVIN MARCIA | SVP, Chief Scientific Officer | A 獲配股票 | 57.5K | – | – | 268K | SEC |
| 2025-02-04 | 02-06 | Ogden Christopher | Chief Financial Officer | A 獲配股票 | 57.5K | – | – | 210K | SEC |
| 2025-02-04 | 02-06 | Ogden Christopher | Chief Financial Officer | A 獲配股票 | 44.0K | – | – | 152K | SEC |
| 2025-02-04 | 02-06 | McCarthy Sean A. | CEO | A 獲配股票 | 195K | – | – | 1.0M | SEC |
| 2025-02-04 | 02-06 | Chu Yu-Waye | Chief Medical Officer | A 獲配股票 | 56.0K | – | – | 82.3K | SEC |
| 2025-02-04 | 02-06 | McCarthy Sean A. | CEO | A 獲配股票 | 180K | – | – | 838K | SEC |
| 2025-02-04 | 02-06 | Chu Yu-Waye | Chief Medical Officer | A 獲配股票 | 57.5K | – | – | 140K | SEC |
| 2025-02-04 | 02-06 | BELVIN MARCIA | SVP, Chief Scientific Officer | A 獲配股票 | 57.5K | – | – | 263K | SEC |
| 2025-02-04 | 02-06 | BELVIN MARCIA | SVP, Chief Scientific Officer | A 獲配股票 | 30.0K | – | – | 206K | SEC |
| 2024-08-20 | 08-22 | McCarthy Sean A. | CEO | S 公開市場賣出 | 13.9K | 1.23 | 17K | 658K | SEC |
| 2024-08-20 | 08-22 | Landau Jeffrey B | Chief Business Officer | S 公開市場賣出 | 4.2K | 1.23 | 5K | 119K | SEC |
| 2024-08-20 | 08-22 | McCarthy Sean A. | CEO | M 選擇權執行 | 37.5K | – | – | 672K | SEC |
| 2024-08-20 | 08-22 | BELVIN MARCIA | SVP, Chief Scientific Officer | S 公開市場賣出 | 4.2K | 1.23 | 5K | 176K | SEC |
| 2024-08-20 | 08-22 | BELVIN MARCIA | SVP, Chief Scientific Officer | M 選擇權執行 | 11.3K | – | – | 180K | SEC |
| 2024-08-20 | 08-22 | ROWLAND LLOYD A | General Counsel | S 公開市場賣出 | 4.2K | 1.23 | 5K | 131K | SEC |
| 2024-08-20 | 08-22 | ROWLAND LLOYD A | General Counsel | M 選擇權執行 | 11.3K | – | – | 135K | SEC |
| 2024-08-20 | 08-22 | Landau Jeffrey B | Chief Business Officer | M 選擇權執行 | 11.3K | – | – | 123K | SEC |
| 2024-08-20 | 08-22 | Ogden Christopher | Chief Financial Officer | S 公開市場賣出 | 2.0K | 1.23 | 2K | 108K | SEC |
| 2024-08-20 | 08-22 | Ogden Christopher | Chief Financial Officer | M 選擇權執行 | 6.9K | – | – | 110K | SEC |
| 2024-06-12 | 06-14 | Ogden Christopher | Chief Financial Officer | A 獲配股票 | 17.5K | – | – | 103K | SEC |
| 2024-03-26 | 03-28 | McCarthy Sean A. | CEO | M 選擇權執行 | 110K | 1.57 | 172K | 634K | SEC |
| 2024-03-19 | 03-21 | BELVIN MARCIA | SVP, Chief Scientific Officer | S 公開市場賣出 | 12.8K | 2.09 | 27K | 169K | SEC |
| 2024-03-19 | 03-21 | Landau Jeffrey B | Chief Business Officer | S 公開市場賣出 | 6.6K | 2.09 | 14K | 110K | SEC |
| 2024-03-19 | 03-21 | Ogden Christopher | SVP, Finance and Accounting | S 公開市場賣出 | 3.0K | 2.09 | 6K | 85.7K | SEC |
| 2024-03-19 | 03-21 | ROWLAND LLOYD A | General Counsel | S 公開市場賣出 | 5.3K | 2.09 | 11K | 118K | SEC |
| 2024-03-19 | 03-21 | McCarthy Sean A. | CEO | S 公開市場賣出 | 20.2K | 2.09 | 42K | 524K | SEC |
| 2024-01-18 | 01-19 | Chu Yu-Waye | Chief Medical Officer | A 獲配股票 | 26.3K | – | – | 26.3K | SEC |
| 2024-01-18 | 01-19 | McCarthy Sean A. | CEO | A 獲配股票 | 90.0K | – | – | 545K | SEC |
| 2024-01-18 | 01-19 | ROWLAND LLOYD A | General Counsel | A 獲配股票 | 25.0K | – | – | 123K | SEC |
| 2024-01-18 | 01-19 | BELVIN MARCIA | SVP, Chief Scientific Officer | A 獲配股票 | 26.3K | – | – | 181K | SEC |
| 2024-01-18 | 01-19 | Ogden Christopher | SVP, Finance and Accounting | A 獲配股票 | 40.0K | – | – | 88.7K | SEC |
| 2024-01-18 | 01-19 | Landau Jeffrey B | Chief Business Officer | A 獲配股票 | 30.0K | – | – | 117K | SEC |
| 2023-12-20 | 12-22 | BELVIN MARCIA | SVP, Chief Scientific Officer | S 公開市場賣出 | 4.1K | 1.38 | 6K | 155K | SEC |
| 2023-12-20 | 12-22 | Landau Jeffrey B | Chief Business Officer | S 公開市場賣出 | 4.1K | 1.38 | 6K | 86.6K | SEC |
| 2023-12-20 | 12-22 | ROWLAND LLOYD A | General Counsel | S 公開市場賣出 | 4.1K | 1.38 | 6K | 98.0K | SEC |
| 2023-12-20 | 12-22 | Ogden Christopher | SVP, Finance and Accounting | S 公開市場賣出 | 2.0K | 1.38 | 3K | 48.7K | SEC |
| 2023-12-20 | 12-22 | McCarthy Sean A. | CEO | S 公開市場賣出 | 13.6K | 1.38 | 19K | 455K | SEC |
| 2023-12-17 | 12-19 | Landau Jeffrey B | Chief Business Officer | M 選擇權執行 | 11.3K | – | – | 90.7K | SEC |
| 2023-12-17 | 12-19 | ROWLAND LLOYD A | General Counsel | M 選擇權執行 | 11.3K | – | – | 102K | SEC |
| 2023-12-17 | 12-19 | McCarthy Sean A. | CEO | M 選擇權執行 | 37.5K | – | – | 468K | SEC |
| 2023-12-17 | 12-19 | BELVIN MARCIA | SVP, Chief Scientific Officer | M 選擇權執行 | 11.3K | – | – | 159K | SEC |
| 2023-12-17 | 12-19 | Ogden Christopher | SVP, Finance and Accounting | M 選擇權執行 | 6.9K | – | – | 50.6K | SEC |
| 2023-09-22 | 09-22 | Landau Jeffrey B | Chief Business Officer | S 公開市場賣出 | 4.1K | 1.30 | 5K | 76.4K | SEC |
| 2023-09-22 | 09-22 | ROWLAND LLOYD A | General Counsel | S 公開市場賣出 | 5.5K | 1.30 | 7K | 80.6K | SEC |
| 2023-09-22 | 09-22 | BELVIN MARCIA | SVP, Chief Scientific Officer | S 公開市場賣出 | 4.1K | 1.30 | 5K | 148K | SEC |
| 2023-09-22 | 09-22 | McCarthy Sean A. | CEO | S 公開市場賣出 | 14.6K | 1.30 | 19K | 431K | SEC |
| 2023-09-20 | 09-22 | McCarthy Sean A. | CEO | A 獲配股票 | 40.0K | – | – | 445K | SEC |
| 2023-09-20 | 09-22 | BELVIN MARCIA | SVP, Chief Scientific Officer | A 獲配股票 | 11.3K | – | – | 152K | SEC |
| 2023-09-20 | 09-22 | ROWLAND LLOYD A | General Counsel | A 獲配股票 | 15.0K | – | – | 86.1K | SEC |
| 2023-09-20 | 09-22 | Landau Jeffrey B | Chief Business Officer | A 獲配股票 | 11.3K | – | – | 80.5K | SEC |
| 2023-05-19 | 05-23 | McCarthy Sean A. | CEO | M 選擇權執行 | 16.5K | 1.57 | 26K | 405K | SEC |
| 2023-03-29 | 03-31 | Jones Elaine V | Director | P 公開市場買進 | 5.0K | 1.55 | 8K | 5.1K | SEC |
| 2023-03-22 | 03-29 | BELVIN MARCIA | SVP, Chief Scientific Officer | A 獲配股票 | 60.0K | – | – | 141K | SEC |
| 2023-03-16 | 03-20 | Landau Jeffrey B | Chief Financial Officer | S 公開市場賣出 | 1.5K | 1.98 | 3K | 69.2K | SEC |
| 2023-03-16 | 03-20 | Peterson Amy C. | EVP, Chief Development Officer | S 公開市場賣出 | 4.3K | 1.98 | 8K | 58.4K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| FMR LLC | 32.7M | 123M | 新進 | 新進 |
| Kynam Capital Management, LP | 21.7M | 81.4M | 新進 | 新進 |
| BlackRock, Inc. | 17.6M | 65.8M | 新進 | 新進 |
| BANK OF AMERICA CORP /DE/ | 15.1M | 56.6M | 新進 | 新進 |
| STATE STREET CORP | 11.7M | 44.1M | 新進 | 新進 |
| PERCEPTIVE ADVISORS LLC | 10.4M | 39.1M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 8.5M | 32.0M | 新進 | 新進 |
| Point72(柯恩) Point72 Asset Management, L.P. | 7.8M | 29.3M | 新進 | 新進 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.2M | 19.4M | 新進 | 新進 |
| Venrock Adviser, LLC | 5.0M | 18.7M | 新進 | 新進 |
| BAKER BROS. ADVISORS LP | 5.0M | 18.7M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 4.7M | 17.5M | 新進 | 新進 |
| Elmind Capital, LP | 4.5M | 17.1M | 新進 | 新進 |
| Nextech Invest Ltd. | 4.4M | 16.7M | 新進 | 新進 |
| Two Sigma TWO SIGMA INVESTMENTS, LP | 4.1M | 15.5M | 新進 | 新進 |
| Eversept Partners, LP | 3.6M | 13.3M | 新進 | 新進 |
| UBS Group AG | 3.5M | 13.0M | 新進 | 新進 |
| Siren, L.L.C. | 3.5M | 13.0M | 新進 | 新進 |
| ADAR1 Capital Management, LLC | 3.4M | 12.6M | 新進 | 新進 |
| 城堡 CITADEL ADVISORS LLC | 3.1M | 11.7M | 新進 | 新進 |
| MARSHALL WACE, LLP | 3.0M | 11.3M | 新進 | 新進 |
| Woodline Partners LP | 2.0M | 7.7M | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 2.0M | 7.5M | 新進 | 新進 |
| DIMENSIONAL FUND ADVISORS LP | 1.9M | 7.0M | 新進 | 新進 |
| Qube Research & Technologies Ltd | 1.8M | 6.8M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 179 +0 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 179 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 213M · 97.9% |
| 合計季末市值 | 800M |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 33.5M |
|---|---|
| 與上期比 | -3.2% |
| 佔流通股數 | 15.38% |
| 日均成交量 | 2.8M |
| 回補天數 | 11.8 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 33.5M | -3.2% | 15.38% | 2.8M | 11.8 |
| 2026-08-14 | 34.6M | -1.4% | 15.89% | 2.2M | 15.9 |
| 2026-07-31 | 35.1M | -12.9% | 16.11% | 3.0M | 11.8 |
| 2026-07-15 | 40.3M | +13.4% | 18.50% | 3.9M | 10.4 |
| 2026-06-30 | 35.6M | +16.2% | 16.32% | 8.2M | 4.3 |
| 2026-06-15 | 30.6M | +6.6% | 14.05% | 3.5M | 8.7 |
| 2026-05-29 | 28.7M | -7.8% | 13.18% | 3.1M | 9.3 |
| 2026-05-15 | 31.1M | +4.7% | 14.29% | 3.0M | 10.3 |
| 2026-04-30 | 29.7M | +8.1% | 13.65% | 3.5M | 8.4 |
| 2026-04-15 | 27.5M | +24.9% | 12.63% | 5.1M | 5.4 |
| 2026-03-31 | 22.0M | +7.9% | 10.11% | 19.4M | 1.1 |
| 2026-03-13 | 20.4M | +8.2% | 9.37% | 2.9M | 7.1 |
| 2026-02-27 | 18.9M | +11.2% | 8.66% | 2.3M | 8.0 |
| 2026-02-13 | 17.0M | +14.5% | 7.78% | 3.6M | 4.7 |
| 2026-01-30 | 14.8M | -8.1% | 6.80% | 4.4M | 3.3 |
| 2026-01-15 | 16.1M | -32.0% | 7.40% | 2.2M | 7.5 |
| 2025-12-31 | 23.7M | +41.3% | 10.88% | 3.6M | 6.6 |
| 2025-12-15 | 16.8M | -2.4% | 7.70% | 1.8M | 9.2 |
| 2025-11-28 | 17.2M | -41.4% | 7.89% | 2.3M | 7.6 |
| 2025-11-14 | 29.3M | +2.1% | 13.46% | 5.2M | 5.6 |
| 2025-10-31 | 28.7M | +1.1% | 13.18% | 2.4M | 12.1 |
| 2025-10-15 | 28.4M | -9.5% | 13.03% | 3.3M | 8.6 |
| 2025-09-30 | 31.4M | +8.3% | 14.39% | 5.6M | 5.6 |
| 2025-09-15 | 29.0M | +7.4% | 13.29% | 2.6M | 11.3 |
| 2025-08-29 | 27.0M | +7.3% | 12.38% | 3.0M | 9.1 |
| 2025-08-15 | 25.1M | +4.9% | 11.54% | 4.5M | 5.6 |